150 related articles for article (PubMed ID: 11306447)
21. Microdosimetric analysis of alpha-particle-emitting targeted radiotherapeutics using histological images.
Akabani G; Kennel SJ; Zalutsky MR
J Nucl Med; 2003 May; 44(5):792-805. PubMed ID: 12732682
[TBL] [Abstract][Full Text] [Related]
22. Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin a-4 3-O-phosphate.
Pedley RB; Hill SA; Boxer GM; Flynn AA; Boden R; Watson R; Dearling J; Chaplin DJ; Begent RH
Cancer Res; 2001 Jun; 61(12):4716-22. PubMed ID: 11406542
[TBL] [Abstract][Full Text] [Related]
23. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
[TBL] [Abstract][Full Text] [Related]
24. Radioimmunotherapy using vascular targeted 213Bi: the role of tumor necrosis factor alpha in the development of pulmonary fibrosis.
Davis IA; Kennel SJ
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3160s-3164s. PubMed ID: 10541358
[TBL] [Abstract][Full Text] [Related]
25. Radioimmunotherapy with alpha-particle emitting 213Bi-C-functionalized trans-cyclohexyl-diethylenetriaminepentaacetic acid-humanized 3S193 is enhanced by combination with paclitaxel chemotherapy.
Kelly MP; Lee FT; Tahtis K; Smyth FE; Brechbiel MW; Scott AM
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5604s-5612s. PubMed ID: 17875796
[TBL] [Abstract][Full Text] [Related]
26. Tumor specificity and in vivo targeting of an antibody against exon 9 deleted E-cadherin in gastric cancer.
Lee HJ; Lee HS; Hur K; Kim WH; Yanagihara K; Becker KF; Lee KU; Yang HK
J Cancer Res Clin Oncol; 2007 Dec; 133(12):987-94. PubMed ID: 17576594
[TBL] [Abstract][Full Text] [Related]
27. Optimizing bispecific antibody pretargeting for use in radioimmunotherapy.
Sharkey RM; Karacay H; Richel H; McBride WJ; Rossi EA; Chang K; Yeldell D; Griffiths GL; Hansen HJ; Goldenberg DM
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3897S-913S. PubMed ID: 14506188
[TBL] [Abstract][Full Text] [Related]
28. E-cadherin expression in sporadic gastric cancer from Mexico: exon 8 and 9 deletions are infrequent events associated with poor survival.
Gamboa-Dominguez A; Dominguez-Fonseca C; Chavarri-Guerra Y; Vargas R; Reyes-Gutierrez E; Green D; Quintanilla-Martinez L; Luber B; Busch R; Becker KF; Becker I; Höfler H; Fend F
Hum Pathol; 2005 Jan; 36(1):29-35. PubMed ID: 15712179
[TBL] [Abstract][Full Text] [Related]
29. Effective alpha-particle-mediated radioimmunotherapy of murine leukemia.
Huneke RB; Pippin CG; Squire RA; Brechbiel MW; Gansow OA; Strand M
Cancer Res; 1992 Oct; 52(20):5818-20. PubMed ID: 1394209
[TBL] [Abstract][Full Text] [Related]
30. Hyaluronidase-induced periodic modulation of the interstitial fluid pressure increases selective antibody uptake in human osteosarcoma xenografts.
Brekken C; Hjelstuen MH; Bruland ØS; de Lange Davies C
Anticancer Res; 2000; 20(5B):3513-9. PubMed ID: 11131655
[TBL] [Abstract][Full Text] [Related]
31. Copper-67 radioimmunotherapy and growth inhibition by anti-L1-cell adhesion molecule monoclonal antibodies in a therapy model of ovarian cancer metastasis.
Knogler K; Grünberg J; Zimmermann K; Cohrs S; Honer M; Ametamey S; Altevogt P; Fogel M; Schubiger PA; Novak-Hofer I
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):603-11. PubMed ID: 17255283
[TBL] [Abstract][Full Text] [Related]
32. In vitro targeting of NG2 antigen by 213Bi-9.2.27 alpha-immunoconjugate induces cytotoxicity in human uveal melanoma cells.
Li Y; Wang J; Rizvi SM; Jager MJ; Conway RM; Billson FA; Allen BJ; Madigan MC
Invest Ophthalmol Vis Sci; 2005 Dec; 46(12):4365-71. PubMed ID: 16303921
[TBL] [Abstract][Full Text] [Related]
33. Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2IT-BAT-Lym-1 immunoconjugates.
Kukis DL; DeNardo GL; DeNardo SJ; Mirick GR; Miers LA; Greiner DP; Meares CF
Cancer Res; 1995 Feb; 55(4):878-84. PubMed ID: 7850803
[TBL] [Abstract][Full Text] [Related]
34. Astatine-211-labeled antibodies for treatment of disseminated ovarian cancer: an overview of results in an ovarian tumor model.
Andersson H; Elgqvist J; Horvath G; Hultborn R; Jacobsson L; Jensen H; Karlsson B; Lindegren S; Palm S
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3914S-21S. PubMed ID: 14506189
[TBL] [Abstract][Full Text] [Related]
35. Influence of tumor-associated E-cadherin mutations on tumorigenicity and metastasis.
Kremer M; Quintanilla-Martinez L; Fuchs M; Gamboa-Dominguez A; Haye S; Kalthoff H; Rosivatz E; Hermannstädter C; Busch R; Höfler H; Luber B
Carcinogenesis; 2003 Dec; 24(12):1879-86. PubMed ID: 12949051
[TBL] [Abstract][Full Text] [Related]
36. Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry.
Nikula TK; McDevitt MR; Finn RD; Wu C; Kozak RW; Garmestani K; Brechbiel MW; Curcio MJ; Pippin CG; Tiffany-Jones L; Geerlings MW; Apostolidis C; Molinet R; Geerlings MW; Gansow OA; Scheinberg DA
J Nucl Med; 1999 Jan; 40(1):166-76. PubMed ID: 9935073
[TBL] [Abstract][Full Text] [Related]
37. Rapid and specific targeting of 125I-labeled B lymphocyte stimulator to lymphoid tissues and B cell tumors in mice.
Riccobene TA; Miceli RC; Lincoln C; Knight Y; Meadows J; Stabin MG; Sung C
J Nucl Med; 2003 Mar; 44(3):422-33. PubMed ID: 12621010
[TBL] [Abstract][Full Text] [Related]
38. Comparison of the radiotoxicity of two alpha-particle-emitting immunoconjugates, terbium-149 and bismuth-213, directed against a tumor-specific, exon 9 deleted (d9) E-cadherin adhesion protein.
Miederer M; Seidl C; Beyer GJ; Charlton DE; Vranjes-Duric S; Comor JJ; Huber R; Nikula T; Apostolidis C; Schuhmacher C; Becker KF; Senekowitsch-Schmidtke R
Radiat Res; 2003 May; 159(5):612-20. PubMed ID: 12710872
[TBL] [Abstract][Full Text] [Related]
39. Non-invasive visualisation of the development of peritoneal carcinomatosis and tumour regression after 213Bi-radioimmunotherapy using bioluminescence imaging.
Buchhorn HM; Seidl C; Beck R; Saur D; Apostolidis C; Morgenstern A; Schwaiger M; Senekowitsch-Schmidtke R
Eur J Nucl Med Mol Imaging; 2007 Jun; 34(6):841-9. PubMed ID: 17206415
[TBL] [Abstract][Full Text] [Related]
40. Efforts to control the errant products of a targeted in vivo generator.
Jaggi JS; Kappel BJ; McDevitt MR; Sgouros G; Flombaum CD; Cabassa C; Scheinberg DA
Cancer Res; 2005 Jun; 65(11):4888-95. PubMed ID: 15930310
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
